Analyze The Efficacy Of Recombinant Human Vascular Endostatin Combined With Chemoradiotherapy In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck

Objective:To analysis the therapeutic efficacy of radiotherapy combined with endostar in the treatment of locally advanced squamous cell carcinoma of the head and neckMethods:From July 2011 to June 2014, Collected the patients,who with locally advanced head and neck squamous cell carcinomas, received chemoradiotherapy combined with endostar in the tumor hospital of yunnan province.91 eligible patients were divided into endostar groups (46 patients) and control group (45 patients).Endostar groups planned treatment consisted of cisplatin (100 mg/m2 on days 1,22 and 43 or 40 mg/m2 weekly)+endostar (7.5 mg/m2 on days 1-14 q21)and a dose of at least 70 Gy (2.0 Gy each time) to the initial field for carcinoma and involved lymph nodes,uninvolved nodal areas of the neck were treated with 44 to 64 Gy (1.6-2.0 Gy each time). Control group planned treatment consisted of cisplatin (100 mg/m2 on days 1,22 and 43 or 40 mg/m2 weekly) and a dose of at least 70 Gy (2.0 Gy each time) to the initial field for carcinoma and involved lymph nodes,uninvolved nodal areas of the neck were treated with 44 to 64 Gy (1.6-2.0 Gy each time).The two groups were compared in terms of objective response rates, disease control rate, progress free survival, overall survival, and acute side effects. Using the University of Washington Quality of Life Questionnaire way to evaluate and use SPSS to analyze. Chi-square test and t text were used for objective response rates, disease control rate and acute side effects. Kaplan—Meier method was used for calculating PFS and OS, and the differences between the two groups were analyzed by Log-Rank test.Results:The objective response rate of endostar group and control group were 87.0%�'� 75.6% respectively (χ~2=1.946,P=0.188),disease control rate of two groups were 97.8%�'�95.6%(χ~2=0.368, P=0.617). The median PFS and OS were 18.7months and 14.7 months(P=0.049),26.8 months and 23.6 months(P=0.128). Two groups adverse effects rate were similar. In mood domain、anxiety domain and total score domain, the score of quality of life is higher than these control group, and the total score has no significant between two groups.Conclusion:Endostar enhanced the radio-sensitivity when it combined with chemoradiotherapy treat locally advanced squamous cell carcinoma of the head and neck. And it dose not increase the risk to adverse events. It can prolong progress free survival and improve the quality of life, but cannot significantly prolonged OS. It will provide more choice to treat squamous cell carcinoma of the head and neck.